No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
STRO240719C5000
- 0.15
- +0.03+25.00%
15min DelayClose Jul 16 11:08 ET
0.15High0.15Low
0.15Open0.12Pre Close1 Volume99 Open Interest5.00Strike Price15.00Turnover303.60%IV26.54%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.2608Delta0.3006Gamma27.13Leverage Ratio-0.0651Theta0.0001Rho7.08Eff Leverage0.0012Vega
Intraday
- 5D
- Daily
News
Express News | Sutro Biopharma Appoints DR. Barbara Leyman as Chief Business Development Officer
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
SOUTH SAN FRANCISCO, Calif., July 9, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 28%
Unfortunately for some shareholders, the Sutro Biopharma, Inc. (NASDAQ:STRO) share price has dived 28% in the last thirty days, prolonging recent pain. The drop over the last 30 days has capped off
Institutional Owners May Take Dramatic Actions as Sutro Biopharma, Inc.'s (NASDAQ:STRO) Recent 17% Drop Adds to One-year Losses
Key Insights Given the large stake in the stock by institutions, Sutro Biopharma's stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in the com
Express News | Vgxi Inc. Announces a Strategic Partnership With Sutro Biopharma Inc. to Support Growing Clinical Pipeline
Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
Comments
$Sutro Biopharma(STRO.US$ Completion of enrollment for Part One of the Phase II/III REFRaME-O1 trial for Luvelta and the anticipation of an update that could affirm its potential, which is estimated to be significantly greater than its competitor, Elahere, in platinum-resistant ovarian cancer (PROC). Bancroft highlights Luvelta’s ability to serve a wider PROC patient base, with the potential to address about 80% of patients expressing folate receptor alpha (FRα), in contr...
4
4
$Sutro Biopharma(STRO.US$ Sutro Biopharma Initiated at Buy by B of A Securities with a PT of 12.00!
Dow Jones· 2 mins ago
Dow Jones· 2 mins ago
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Sutro Biopharma(STRO.US$ Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire· 10 mins ago
GlobeNewswire· 10 mins ago
1
$Sutro Biopharma(STRO.US$ Sutro Biopharma Inc (STRO) has provided an announcement.
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
1
2
Read more
TrytosaveabitOP amiable Llama_6295: Yes it is! I sold for like 17% green! And haven’t got back in yet! It’s on my “ update look at your notes “ list! That I was supposed to look at this past weekend! Hehehe. But got busy doing stuff around the house! Hehehe. GL
Arrayfunction : Interesting this news caused so much of a kerfuffle. Getting the participants and starting phase II means they still haven't proved it actually works yet
TrytosaveabitOP Arrayfunction: The early data suggests, so far anyway, that it could end up being the standard for care? But yes if. And it a long way from that. But this is how it moves forward
Arrayfunction TrytosaveabitOP: You are definitely correct there! It's crazy how much of bio-tech is effectively just setting money on fire and hoping for the best!
My thoughts were more around the high risk approach they are taking running phase II/III at the same time. That signals to me either they are extremely confident about the drug based on unreleased efficacy data and want to double-time on getting it to market or the company has decided it is closing its doors regardless of the outcome (so either getting a patent to sell or going bankrupt)
The 2nd one is a lot more likely given the mountain of extra red tape running simultaneously adds - so not going near it as a long investor. But I hope your king of swing style can get some good returns on it!